Revenue Acceleration
Total revenue grew 19.0% YoY to $3,605.4M in Q1 2026 from $3,028.7M in Q1 2025, reflecting strong underlying demand across Regeneron's product portfolio and continued commercial momentum.
REGENERON PHARMACEUTICALS, INC. is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: Regeneron delivered strong Q1 2026 revenue growth of 19.0% YoY to $3.61B, driven by robust product demand, but net income declined 10.1% to $727.2M as R&D spending surged 16.3% and current liabilities jumped 43.2%.
Drawn from management commentary in the Q1 2026 10-Q:
Total revenue grew 19.0% YoY to $3,605.4M in Q1 2026 from $3,028.7M in Q1 2025, reflecting strong underlying demand across Regeneron's product portfolio and continued commercial momentum.
R&D expenses climbed 16.3% YoY to $1,543.5M, representing approximately 42.8% of total revenue, underscoring Regeneron's aggressive pipeline investment strategy which is compressing near-term profitability.
Operating margin contracted approximately 170 basis points YoY to 17.8% from 19.5%, as the rapid growth in R&D and operating expenses outpaced revenue expansion, signaling deliberate reinvestment over short-term earnings optimization.
Revenue
$3.61B
++19.04% YoY
EPS (Basic)
$6.99
-7.78% YoY
Operating Income
$642.9M
++8.65% YoY
Add REGN to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.